IRD Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

6 Analyst Rating

Wall Street analysts forecast IRD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IRD is 8.00 USD with a low forecast of 6.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

6.00

Averages

8.00

High

9.00

Current: 0.000

Low

6.00

Averages

8.00

High

9.00

B. Riley

NULL -> Buy

initiated

2025-12-09

Reason

B. Riley

Price Target

2025-12-09

initiated

NULL -> Buy

Reason

B. Riley initiated coverage of Opus Genetics with a Buy rating and $9 price target.

Piper Sandler

Overweight

initiated

2025-11-25

Reason

Piper Sandler

Price Target

2025-11-25

initiated

Overweight

Reason

Piper Sandler initiated coverage of Opus Genetics with an Overweight rating and $7 price target. The company has demonstrated early efficacy data for its lead gene therapy program, OPGx-LCA5, in Leber congenital amaurosis type 5, where there are currently no treatment options and a high unmet need, the analyst tells investors in a research note. In addition, Piper says Opus' second gene therapy program, OPGx-BEST1 for BEST1-related inherited retinal diseases, has promising preclinical data.

Wedbush

Yun Zhong

Outperform

initiated

2025-10-29

Reason

Wedbush

Yun Zhong

Price Target

2025-10-29

initiated

Outperform

Reason

As previously reported, Wedbush analyst Yun Zhong initiated coverage of Opus Genetics with an Outperform rating and $8 price target. The October 2024 deal to combine the previous private Opus with Ocuphire "created a unique company with two distinctive approaches and a strong focus on ophthalmology indications," the analyst tells investors in a research note. The firm sees an over $10B market opportunity for Opus' gene therapy portfolio. It believes clinical and regulatory updates in in the coming months will serve as "strong catalysts" to drive continued share outperformance.

Wedbush

NULL -> Outperform

initiated

2025-10-29

Reason

Wedbush

Price Target

2025-10-29

initiated

NULL -> Outperform

Reason

Wedbush initiated coverage of Opus Genetics with an Outperform rating and $8 price target.

Chardan

NULL -> Buy

initiated

2025-10-16

Reason

Chardan

Price Target

2025-10-16

initiated

NULL -> Buy

Reason

Chardan initiated coverage of Opus Genetics with a Buy rating and $9 price target. The firm cites the commercial potential of the company's gene therapy assets, including OPGx-LCA5 for Leber congenital amaurosis type 5 and OPGx-BEST1 for bestrophinopathies, along with additional upside potential from its partnered phentolamine small molecule programs for the Buy rating.

Lucid Capital

Dev Prasad

Buy

initiated

2025-06-18

Reason

Lucid Capital

Dev Prasad

Price Target

2025-06-18

initiated

Buy

Reason

Lucid Capital analyst Dev Prasad initiated coverage of Opus Genetics with a Buy rating and $5 price target. The company's lead program, OPGx-LCA5, is being evaluated in a Phase 1/2 trial for LCA5-associated Leber congenital amaurosis, which affects approximately 200 patients in the U.S., the analyst tells investors in a research note. The firm says Interim adult data have shown "encouraging" safety and efficacy results, and the ongoing pediatric cohort could provide additional validation, with initial data from all three pediatric patients expected in Q3.

Valuation Metrics

The current forward P/E ratio for Opus Genetics Inc (IRD.O) is -4.73, compared to its 5-year average forward P/E of -2.15. For a more detailed relative valuation and DCF analysis to assess Opus Genetics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.15

Current PE

-4.73

Overvalued PE

-0.78

Undervalued PE

-3.52

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.03

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.15

Undervalued EV/EBITDA

-0.08

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

4.69

Current PS

10.24

Overvalued PS

7.65

Undervalued PS

1.73

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders areBuying! The selling amount has increased 231.65% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 2167.49% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areBuying! The selling amount has increased 231.65% over the last month.

Sold

Bought

IRD News & Events

Events Timeline

No data

News

5.0

01-02NASDAQ.COM

Opus Genetics Insider Cam Gallagher Acquires 164,000 Shares of IRD for $323,693

5.0

2025-12-16Globenewswire

Opus Genetics Grants 50,000 Stock Options to Attract New Employee

1.0

2025-12-11Globenewswire

Opus Genetics CEO to Present at J.P. Morgan 2026 Healthcare Conference on January 15, 2026

People Also Watch

Frequently Asked Questions

What is Opus Genetics Inc (IRD) stock price today?

The current price of IRD is 1.93 USD — it has decreased -3.5 % in the last trading day.

What is Opus Genetics Inc (IRD)'s business?

Opus Genetics, Inc. is a clinical-stage ophthalmic biotechnology company. The Company is engaged in developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. The Company’s pipeline includes adeno-associated virus (AAV)-based investigational gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Its pipeline also includes OPGx-BEST1 investigational gene therapy, designed to address mutations in the BEST1 gene, which is associated with retinal degeneration. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist being investigated to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 being investigated to slow the progression of non-proliferative diabetic retinopathy.

What is the price predicton of IRD Stock?

What is Opus Genetics Inc (IRD)'s revenue for the last quarter?

Opus Genetics Inc revenue for the last quarter amounts to 3.08M USD, decreased -20.38 % YoY.

What is Opus Genetics Inc (IRD)'s earnings per share (EPS) for the last quarter?

Opus Genetics Inc. EPS for the last quarter amounts to -0.25 USD, decreased -13.79 % YoY.

What changes have occurred in the market's expectations for Opus Genetics Inc (IRD)'s fundamentals?

The market is revising Downward the revenue expectations for Opus Genetics, Inc. (IRD) for FY2025, with the revenue forecasts being adjusted by -5.88% over the past three months. During the same period, the stock price has changed by -3.02%.

How many employees does Opus Genetics Inc (IRD). have?

Opus Genetics Inc (IRD) has 18 emplpoyees as of January 10 2026.

What is Opus Genetics Inc (IRD) market cap?

Today IRD has the market capitalization of 133.10M USD.